Skip to main content
Erschienen in: Journal of Neurology 9/2009

01.09.2009 | Original Communication

Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients

verfasst von: Inês Esteves Baldeiras, Maria Helena Ribeiro, Paula Pacheco, Álvaro Machado, Isabel Santana, Luís Cunha, Catarina Resende Oliveira

Erschienen in: Journal of Neurology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

The clinical diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD) is difficult, and reliable markers are highly desired. In this work we assess the value of several cerebrospinal fluid (CSF) markers for sCJD diagnosis. Within the framework of the Portuguese Epidemiological Surveillance Program for Human Prion Diseases, CSF samples from 71 patients with clinically suspected sCJD, 30 definite sCJD and 41 non-CJD patients, were analysed for the presence of 14-3-3 protein. CSF levels of tau (t-tau), and phosphorylated tau (p-tau181), S-100b and β amyloid (Aβ42) proteins were determined. The influence of clinical and genetic characteristics on CSF markers sensitivity was also evaluated. Protein 14-3-3 was detected in 29/30 sCJD patients and 9/41 non-CJD patients. Extremely elevated t-tau and S-100b protein levels were found in sCJD patients, while p-tau181 levels were only slightly elevated and Aβ42 showed no differences compared to controls. 14-3-3 was the most sensitive parameter (97%), but its specificity was low (78%); sensitivity/specificity for other proteins were: S-100b—93/93%, t-tau—93/95%, with maximum accuracy being obtained by a combination of tests (14-3-3 combined with either t-tau or S-100b, or combining S-100b with t-tau/Aβ42 or p-tau/t-tau ratios). The sensitivity of 14-3-3, as well as of p-tau181/t-tau ratio, was decreased in younger patients with long disease duration, with the PrP-2 isotype and MV genotype. Both 14-3-3, t-tau and S-100b are sensitive markers for sCJD, but 14-3-3 specificity seems to be lower in this special clinical setting of rapidly progressing dementias. We propose that in cases with a 14-3-3 weak positive result, or in young patients with long disease duration, a second CSF marker would be valuable for the diagnosis of sCJD.
Literatur
1.
Zurück zum Zitat Amouyel P, Vidal O, Launay JM, Laplanche JL (1994) The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt–Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 344:1315–1318. doi:10.1016/S0140-6736(94)90691-2 PubMedCrossRef Amouyel P, Vidal O, Launay JM, Laplanche JL (1994) The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt–Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 344:1315–1318. doi:10.​1016/​S0140-6736(94)90691-2 PubMedCrossRef
2.
Zurück zum Zitat Blennow K, Johansson A, Zetterberg H (2005) Diagnostic value of 14-3-3β immunoblot and T-tau/P-tau ratio in clinically suspected Cretzfeldt–Jakob disease. Int J Mol Med 16:1147–1149PubMed Blennow K, Johansson A, Zetterberg H (2005) Diagnostic value of 14-3-3β immunoblot and T-tau/P-tau ratio in clinically suspected Cretzfeldt–Jakob disease. Int J Mol Med 16:1147–1149PubMed
3.
Zurück zum Zitat Bosco P, Guéant-Rodriguez RM, Anello G, Spada RS, Romano A, Caraci F, Ferri R, Guéant JL (2005) Allele epsilon 4 of ApoE is a stronger predictor of Alzheimer risk in Sicily than in continental South Italy. Neurosci Lett 388:168–172PubMed Bosco P, Guéant-Rodriguez RM, Anello G, Spada RS, Romano A, Caraci F, Ferri R, Guéant JL (2005) Allele epsilon 4 of ApoE is a stronger predictor of Alzheimer risk in Sicily than in continental South Italy. Neurosci Lett 388:168–172PubMed
4.
Zurück zum Zitat Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Kl Jellinger (1995) Neuropathological diagnostic criteria for Creutzfeldt–Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5:459–466. doi:10.1111/j.1750-3639.1995.tb00625.x PubMedCrossRef Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Kl Jellinger (1995) Neuropathological diagnostic criteria for Creutzfeldt–Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5:459–466. doi:10.​1111/​j.​1750-3639.​1995.​tb00625.​x PubMedCrossRef
5.
Zurück zum Zitat Buerger K, Otto M, Teiperl SJ, Zinkowski R, Blennow K, DeBernardis J, Kerkman D, Schröeder J, Schönknecht P, Cepek L, McCulloch C, Möller HJ, Wiltfang J, Kretzschmar H, Hampel H (2006) Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease. Neurobiol Aging 27:10–15. doi:10.1016/j.neurobiolaging.2004.12.003 PubMedCrossRef Buerger K, Otto M, Teiperl SJ, Zinkowski R, Blennow K, DeBernardis J, Kerkman D, Schröeder J, Schönknecht P, Cepek L, McCulloch C, Möller HJ, Wiltfang J, Kretzschmar H, Hampel H (2006) Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease. Neurobiol Aging 27:10–15. doi:10.​1016/​j.​neurobiolaging.​2004.​12.​003 PubMedCrossRef
6.
Zurück zum Zitat Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF (2001) CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56:1528–1533PubMed Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF (2001) CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56:1528–1533PubMed
7.
Zurück zum Zitat Chapman T, McKeel DW Jr, Morris JC (2000) Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt–Jakob disease. Neurology 55:1396–1397PubMed Chapman T, McKeel DW Jr, Morris JC (2000) Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt–Jakob disease. Neurology 55:1396–1397PubMed
9.
Zurück zum Zitat Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E, Mitrova E, Alpérovitch A, Brandel JP, Mackenzie J, Murray K, Will RG (2006) Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt–Jakob disease. Brain 129:2278–2287. doi:10.1093/brain/awl159 PubMedCrossRef Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E, Mitrova E, Alpérovitch A, Brandel JP, Mackenzie J, Murray K, Will RG (2006) Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt–Jakob disease. Brain 129:2278–2287. doi:10.​1093/​brain/​awl159 PubMedCrossRef
11.
Zurück zum Zitat Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL (2003) Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease. Arch Neurol 60:813–816. doi:10.1001/archneur.60.6.813 PubMedCrossRef Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL (2003) Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease. Arch Neurol 60:813–816. doi:10.​1001/​archneur.​60.​6.​813 PubMedCrossRef
12.
Zurück zum Zitat Goodall CA, Head MW, Everington D, Ironside JW, Knight RSG, Green AJE (2006) Raised CSF phospho-tau concentrations in variant Creutzfeldt–Jakob disease: diagnostic and pathological implications. J Neurol Neurosurg Psychiatry 77:89–91. doi:10.1136/jnnp.2005.065755 PubMedCrossRef Goodall CA, Head MW, Everington D, Ironside JW, Knight RSG, Green AJE (2006) Raised CSF phospho-tau concentrations in variant Creutzfeldt–Jakob disease: diagnostic and pathological implications. J Neurol Neurosurg Psychiatry 77:89–91. doi:10.​1136/​jnnp.​2005.​065755 PubMedCrossRef
13.
Zurück zum Zitat Green AJ, Ramljak S, Muller WE, Knoght RS, Schroeder HC (2002) 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt–Jakob disease measured using a capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett 324:57–60. doi:10.1016/S0304-3940(02)00172-6 PubMedCrossRef Green AJ, Ramljak S, Muller WE, Knoght RS, Schroeder HC (2002) 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt–Jakob disease measured using a capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett 324:57–60. doi:10.​1016/​S0304-3940(02)00172-6 PubMedCrossRef
14.
Zurück zum Zitat Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, Ironside JW, Will JG, Knight RS (2001) Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt–Jakob disease. J Neurol Neurosurg Psychiatry 70:744–748. doi:10.1136/jnnp.70.6.744 PubMedCrossRef Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, Ironside JW, Will JG, Knight RS (2001) Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt–Jakob disease. J Neurol Neurosurg Psychiatry 70:744–748. doi:10.​1136/​jnnp.​70.​6.​744 PubMedCrossRef
15.
17.
Zurück zum Zitat Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001) Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 71:401–403. doi:10.1136/jnnp.71.3.401 PubMedCrossRef Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001) Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 71:401–403. doi:10.​1136/​jnnp.​71.​3.​401 PubMedCrossRef
19.
Zurück zum Zitat Lemstra AW, van Meegen MT, Vreyling JP, Meijering PH, Jansen GH, Bulk S, Baas F, van Gool WA (2000) 14-3-3 testing in diagnosing Creutzfeldt–Jakob disease: a prospective study in 112 patients. Neurology 55:514–516PubMed Lemstra AW, van Meegen MT, Vreyling JP, Meijering PH, Jansen GH, Bulk S, Baas F, van Gool WA (2000) 14-3-3 testing in diagnosing Creutzfeldt–Jakob disease: a prospective study in 112 patients. Neurology 55:514–516PubMed
21.
Zurück zum Zitat Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mäder M, Weber T (1997) S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. J Neurol 244:566–570. doi:10.1007/s004150050145 PubMedCrossRef Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mäder M, Weber T (1997) S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. J Neurol 244:566–570. doi:10.​1007/​s004150050145 PubMedCrossRef
22.
Zurück zum Zitat Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 58:192–197PubMed Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 58:192–197PubMed
23.
Zurück zum Zitat Panza F, Díntrono A, Colacicco AM, Capruso C, Basile AM, Capurso S, Capurso A, Solfrizzi V (2004) Regional European differences in allele and genotype frequencies of low density lipoprotein receptor-related protein 1 polymorphism in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 126:69–73. doi:10.1002/ajmg.b.20146 CrossRef Panza F, Díntrono A, Colacicco AM, Capruso C, Basile AM, Capurso S, Capurso A, Solfrizzi V (2004) Regional European differences in allele and genotype frequencies of low density lipoprotein receptor-related protein 1 polymorphism in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 126:69–73. doi:10.​1002/​ajmg.​b.​20146 CrossRef
24.
25.
Zurück zum Zitat Pocchiari M, Poupolo M, Croes EA, Budka H, Gelpi E, Collins S, Lewis V, Sutcliffe T, Guilivi A, Delasnerie-Laupretre N, Brandel JP, Alperovitch A, Zerr I, Poser S, Kretzschmar HA, Ladogana A, Rietvald I, Mitrova E, Martinez-Martin P, de Pedro-Cuesta J, Glatzel M, Aguzzi A, Cooper S, Mackenzie J, van Duijn CM, Will RG (2004) Predictors of survival in sporadic Creutzfeldt–Jakob disease and other human transmissible spongiform encephalopathies. Brain 127:2348–2359. doi:10.1093/brain/awh249 PubMedCrossRef Pocchiari M, Poupolo M, Croes EA, Budka H, Gelpi E, Collins S, Lewis V, Sutcliffe T, Guilivi A, Delasnerie-Laupretre N, Brandel JP, Alperovitch A, Zerr I, Poser S, Kretzschmar HA, Ladogana A, Rietvald I, Mitrova E, Martinez-Martin P, de Pedro-Cuesta J, Glatzel M, Aguzzi A, Cooper S, Mackenzie J, van Duijn CM, Will RG (2004) Predictors of survival in sporadic Creutzfeldt–Jakob disease and other human transmissible spongiform encephalopathies. Brain 127:2348–2359. doi:10.​1093/​brain/​awh249 PubMedCrossRef
26.
Zurück zum Zitat Poser S, Mollenhauer B, Kraubeta A, Zerr I, Steinhoff BJ, Schroeter A, Finkenstaedt M, Schulz-Schaeffer WJ, Kretzschmar HA, Felgenhauer K (1999) How to improve the clinical diagnosis of Creutzfeldt–Jakob disease. Brain 12:2345–2351. doi:10.1093/brain/122.12.2345 CrossRef Poser S, Mollenhauer B, Kraubeta A, Zerr I, Steinhoff BJ, Schroeter A, Finkenstaedt M, Schulz-Schaeffer WJ, Kretzschmar HA, Felgenhauer K (1999) How to improve the clinical diagnosis of Creutzfeldt–Jakob disease. Brain 12:2345–2351. doi:10.​1093/​brain/​122.​12.​2345 CrossRef
28.
Zurück zum Zitat Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Förstl H, Kurz A (2003) Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias. Mol Psychiatry 8:343–347. doi:10.1038/sj.mp.4001220 PubMedCrossRef Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Förstl H, Kurz A (2003) Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias. Mol Psychiatry 8:343–347. doi:10.​1038/​sj.​mp.​4001220 PubMedCrossRef
30.
Zurück zum Zitat Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I (2006) CSF tests in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 67:637–643. doi:10.1212/01.wnl.0000230159.67128.00 PubMedCrossRef Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I (2006) CSF tests in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 67:637–643. doi:10.​1212/​01.​wnl.​0000230159.​67128.​00 PubMedCrossRef
31.
Zurück zum Zitat Sanchez-Juan P, Sanchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrová E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Krasnianski A, Equestre M, Slivarichová D, Saiz A, Calero M, Pocchiari M, Knight R, van Dujin C, Zerr I (2007) Influence of timing on CSF tests value for Cretzfeldt–Jakob disease diagnosis. J Neurol 254:901–906. doi:10.1007/s00415-006-0472-9 PubMedCrossRef Sanchez-Juan P, Sanchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrová E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Krasnianski A, Equestre M, Slivarichová D, Saiz A, Calero M, Pocchiari M, Knight R, van Dujin C, Zerr I (2007) Influence of timing on CSF tests value for Cretzfeldt–Jakob disease diagnosis. J Neurol 254:901–906. doi:10.​1007/​s00415-006-0472-9 PubMedCrossRef
32.
Zurück zum Zitat Satoh K, Shirabe S, Eguchi H, Tsujino A, Eguchi K, Satoh A, Tsujihata M, Niwa M, Katamine S, Kurihara S, Matsuo H (1995) 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol 26:45–52. doi:10.1007/s10571-006-9370-z CrossRef Satoh K, Shirabe S, Eguchi H, Tsujino A, Eguchi K, Satoh A, Tsujihata M, Niwa M, Katamine S, Kurihara S, Matsuo H (1995) 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol 26:45–52. doi:10.​1007/​s10571-006-9370-z CrossRef
33.
Zurück zum Zitat Satoh K, Shirabe S, Tsujino A, Eguchi H, Motomura M, Honda H, Tomita I, Satoh A, Tsujihata M, Matsuo H, Nakagawa M, Eguchi K (2007) Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord 24:207–212. doi:10.1159/000107082 PubMedCrossRef Satoh K, Shirabe S, Tsujino A, Eguchi H, Motomura M, Honda H, Tomita I, Satoh A, Tsujihata M, Matsuo H, Nakagawa M, Eguchi K (2007) Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord 24:207–212. doi:10.​1159/​000107082 PubMedCrossRef
34.
Zurück zum Zitat Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA (2004) Diagnostic value of periodic complexes in Creutzfeldt–Jakob disease. Ann Neurol 56:702–708. doi:10.1002/ana.20261 PubMedCrossRef Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA (2004) Diagnostic value of periodic complexes in Creutzfeldt–Jakob disease. Ann Neurol 56:702–708. doi:10.​1002/​ana.​20261 PubMedCrossRef
35.
Zurück zum Zitat Uro-Coste E, Cassard H, Simon S, Lugan S, Bilheude JM, Perret-Liaudet A, Ironside JW, Haik S, Basset-Leobon C, Lacroux C, Peoch K, Streichenberger N, Langeveld J, Head MW, Grassi J, Hauw JJ, Schelcher F, Delisle MB, Andréoletti O (2008) Beyond PrPres type 1/type 2 dichotomy in Creutzfeldt–Jakob disease. PLoS Pathog 4:e1000029. doi:10.1371/journal.ppat.1000029 CrossRef Uro-Coste E, Cassard H, Simon S, Lugan S, Bilheude JM, Perret-Liaudet A, Ironside JW, Haik S, Basset-Leobon C, Lacroux C, Peoch K, Streichenberger N, Langeveld J, Head MW, Grassi J, Hauw JJ, Schelcher F, Delisle MB, Andréoletti O (2008) Beyond PrPres type 1/type 2 dichotomy in Creutzfeldt–Jakob disease. PLoS Pathog 4:e1000029. doi:10.​1371/​journal.​ppat.​1000029 CrossRef
37.
Zurück zum Zitat Van Everbroeck B, Croses EA, Pals P, Dermaut B, Jansen G, van Dujin CM, Cruts M, van Broeckhoven C, Martin JJ, Cras P (2001) Influence of the prion protein and the apolipoprotein E genotype on the Creutzfelt–Jakob disease phenotype. Neurosci Lett 313:69–72. doi:10.1016/S0304-3940(01)02264-9 PubMedCrossRef Van Everbroeck B, Croses EA, Pals P, Dermaut B, Jansen G, van Dujin CM, Cruts M, van Broeckhoven C, Martin JJ, Cras P (2001) Influence of the prion protein and the apolipoprotein E genotype on the Creutzfelt–Jakob disease phenotype. Neurosci Lett 313:69–72. doi:10.​1016/​S0304-3940(01)02264-9 PubMedCrossRef
38.
Zurück zum Zitat Van Everbroeck B, Green AJE, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R, Cuadrado Corrales N, Martin JJ, Cras P (2002) Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 73:79–82. doi:10.1136/jnnp.73.1.79 PubMedCrossRef Van Everbroeck B, Green AJE, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R, Cuadrado Corrales N, Martin JJ, Cras P (2002) Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 73:79–82. doi:10.​1136/​jnnp.​73.​1.​79 PubMedCrossRef
39.
40.
Zurück zum Zitat Weber T (2000) Clinical and laboratory diagnosis of Creutzfeldt–Jakob disease. Clin Neuropathol 19:249–250PubMed Weber T (2000) Clinical and laboratory diagnosis of Creutzfeldt–Jakob disease. Clin Neuropathol 19:249–250PubMed
41.
Zurück zum Zitat World Health Organization. Report of a WHO consultation on global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies. WHO, Geneva, 8–11 February 1998 World Health Organization. Report of a WHO consultation on global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies. WHO, Geneva, 8–11 February 1998
42.
Zurück zum Zitat Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt–Jakob disease. Ann Neurol 43:32–40. doi:10.1002/ana.410430109 PubMedCrossRef Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt–Jakob disease. Ann Neurol 43:32–40. doi:10.​1002/​ana.​410430109 PubMedCrossRef
43.
44.
Zurück zum Zitat Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T (1996) Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt–Jakob disease. Arch Neurol 53:1233–1238PubMed Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T (1996) Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt–Jakob disease. Arch Neurol 53:1233–1238PubMed
Metadaten
Titel
Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients
verfasst von
Inês Esteves Baldeiras
Maria Helena Ribeiro
Paula Pacheco
Álvaro Machado
Isabel Santana
Luís Cunha
Catarina Resende Oliveira
Publikationsdatum
01.09.2009
Verlag
D. Steinkopff-Verlag
Erschienen in
Journal of Neurology / Ausgabe 9/2009
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-009-5160-0

Weitere Artikel der Ausgabe 9/2009

Journal of Neurology 9/2009 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.